8 news items
Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
VKTX
4 Jun 24
with cardiovascular risk. These results support prior data demonstrating that VK2809 may offer a cardio-protective benefit through its robust reduction
Viking Therapeutics to Participate at Upcoming Investor Conferences
VKTX
30 May 24
and tolerability profile as well as positive signs of clinical benefit. The company is also evaluating an oral formulation of VK2735 in a Phase 1 trial
Ligand Reports First Quarter 2024 Financial Results
AMGN
CASI
JAZZ
7 May 24
equity investments in public companies, excess tax benefit from share-based compensation, income tax effect of adjusted reconciling items and others
Viking Therapeutics Reports Q1 Results: 'An Exceptional Period' Says CEO
VKTX
24 Apr 24
studies, stock-based compensation, salaries and benefits and services provided by third-party consultants.
Viking ended the first quarter
Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
VKTX
24 Apr 24
, the company believes that further benefits might be anticipated from longer dosing periods. To this end, Viking plans to initiate a Phase 2 trial in patients
pzzroasj 3as4wp7y6ojwp46xszsyq40ym8f
ATNM
AZN
BMY
18 Apr 24
biotech sector continues to benefit from favorable financing conditions and a vibrant outlook for mergers and acquisitions, coupled with innovative
rd1qzuyqg8r7wt0k2wv49wpvb4rj116c5p0a6pi 27iv
VKTX
17 Apr 24
and tolerability profile as well as positive signs of clinical benefit. The company is also evaluating an oral formulation of VK2735 in a Phase 1 trial
9ms1ahld25n o63
VKTX
26 Mar 24
of the glucose-dependent insulinotropic peptide (GIP) receptor as a means of enhancing the therapeutic benefits of GLP-1 receptor activation. Tirzepatide
- Prev
- 1
- Next